SEC FORM 4
$10,050.94
enGene Therapeutics Inc. (ENGN)
Purchase of 5,102 shares at $1.97 per share.
Reporting Person Grossman William · Officer Title Interim Chief Medical Officer · Transaction Code P
Traded Sep 22, 2026 · Disclosed Sep 24, 2026
Source: SEC Form 4 · 0001552781-26-000501 · filed 2026-09-24 · View filing →